Amylyx Pharmaceuticals financials
$29.28−1.91%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | $416.0K | -$1.0M | $88.6M | $108.4M | $102.7M |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | -$393.0K | -$8.4M | -$27.8M | $99.1M | $97.5M |
| Gross margin | — | — | — | — | — | — | — | −94.5% | 825.1% | −31.3% | 91.4% | 94.9% |
| Operating income | -$45.7M | -$43.8M | -$36.6M | -$36.0M | -$42.9M | -$37.8M | — | -$75.7M | -$76.3M | -$122.1M | $1.9M | $18.7M |
| Net income | -$43.4M | -$41.3M | -$33.0M | -$34.4M | -$41.4M | -$35.9M | — | -$72.7M | -$72.7M | -$118.8M | $4.7M | $20.9M |
| Net margin | — | — | — | — | — | — | — | −17476.9% | 7106.5% | −134.0% | 4.4% | 20.3% |
| Diluted EPS | $-0.39 | $-0.37 | $-0.30 | $-0.37 | $-0.46 | $-0.42 | — | $-1.07 | $-1.07 | $-1.75 | $0.07 | $0.30 |
| EBITDA | -$45.6M | -$43.7M | -$36.5M | -$35.9M | -$42.7M | -$37.6M | $160.0K | -$75.4M | -$53.2M | -$121.8M | $2.2M | $19.0M |
| Operating cash flow | -$31.4M | -$36.9M | -$27.9M | -$30.4M | -$25.2M | -$39.8M | -$59.0M | -$41.6M | -$66.6M | -$489.0K | $13.6M | -$5.2M |
| Free cash flow | -$31.5M | -$36.9M | -$28.0M | -$30.4M | -$25.3M | -$39.8M | -$59.0M | -$41.6M | -$66.7M | -$556.0K | $13.2M | -$5.5M |
| Diluted shares | 111.2M | 110.6M | 110.1M | 93.3M | 89.1M | 85.7M | 68.6M | 68.1M | 68.0M | 67.9M | 69.2M | 69.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $49.3M | $229.1M | $226.7M | $225.2M | $58.1M | $59.8M |
| Short-term investments | $201.4M | $50.6M | $90.3M | $118.8M | $122.7M | $144.3M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $264.6M | $293.6M | $332.6M | $362.7M | $194.6M | $219.7M |
| Total liabilities | $25.4M | $20.4M | $27.4M | $30.7M | $26.7M | $18.3M |
| Shareholders' equity | $239.2M | $273.2M | $305.3M | $332.0M | $167.9M | $201.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology